FSRH CHC guideline
This concise updated summary of the FRSH combined hormonal contraception guideline covers use, effectiveness, non-contraceptive benefits, and risks
FSRH overweight, obesity, and contraception guideline
Covering evidence-based recommendations on the provision of contraception to women who are overweight or obese
BSPID/EFP oral health and pregnancy guideline
A short, useful summary of key oral health recommendations for pregnant women from the British Society of Periodontology
FSRH emergency contraception guideline
This summary of FSRH EC guidance compares the effectiveness of EC methods and decision-making based on patients’ needs, including helpful algorithms.
SIGN guideline on bacterial UTIs in women
This guidance provides advice on the managment of suspected bacterial lower urinary tract infection in adult women
FSRH UKMEC contraception guideline
A summary of the FSRH UKMEC guidance on the safety of contraceptive methods, which is set out in clear and concise tables.
NICE CKS candida—female genital
This summary has been developed for use by community pharmacists under our Guidelines for Pharmacy title and therefore only covers the information relevant to this setting.
NICE menopause guideline
This summary covers diagnosis, treatment options, and includes a useful care algorithm for the management of menopause.
NICE recommendations for women with urinary incontinence
Summary of NICE guidance covers history taking, assessing urinary incontinence, investigations, non-surgical management, and indicators for referral
Uncomplicated recurrent UTI guideline
This guideline was developed by a multidisciplinary expert panel: Rees J et al with the support of a grant from Aspire Pharma Ltd.
Resource hub
Making the case for preconception care
Having a smear test—what is it about?
Human papillomavirus (HPV) vaccination and cervical cancer—addressing the myths
Your guide to staying active in pregnancy
Pain and symptom diary
- Previous
- Next
Educational resources
Prescribing hormone replacement therapy (HRT) in postmenopausal women: a focus on Oestrogel® (estradiol) and Utrogestan® 100 mg (micronised progesterone)
This prescribing supplement has been commissioned and funded by Besins Healthcare (UK) Ltd and developed in partnership with Guidelines. Includes promotional information.
View prescribing and adverse event reporting information
OES/2021/001a October 2021
For healthcare professionals only.
Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone
This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021
Osteoporotic fracture guideline
This guideline was developed by a multidisciplinary expert panel: Cooper C et al with the support of an educational grant from UCB Pharma Ltd.
Women of child-bearing age with inflammatory rheumatic diseases guideline
This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.
The importance of the progestogenic component of hormone replacement therapy in women with a uterus
Dr John Stevenson and Dr Sophia Tsiligiannis discuss progestogen prescribing in hormone replacement therapy.